Pozelimab is a human monoclonal IgG4 antibody used to treat CD55-deficient protein-losing enteropathy (PLE) or CHAPLE disease. CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.
- Mechanism
- Curator reviewed · 1 reference
Pozelimab-bbfg is a human, monoclonal immunoglobulin G4P (IgG4P) antibody directed against the terminal complement protein C5 that inhibits terminal complement activation by blocking cleavage of C5 into C5a (anaphylatoxin) and C5b, thereby blocking the formation of the membrane-attack complex (C5b-C9, a structure mediating cell lysis).
- Primary indication
- Pozelimab is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.Curator reviewed · 1 structured indication
- Formula / weight
- 145000.0 Da
- First approval
- United States, 2023
- Code names
- REGN3918
- Brand names
Resolves to
What you can answer from here — as of September 02, 2023
Which drugs share a target with Pozelimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account